Paul Tudor Jones's IBRX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 573,021 shares of ImmunityBio, Inc. (IBRX) worth $4.4 M, representing 0.01% of the portfolio. First purchased in 2022-Q2, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in IBRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 573,021 shares. Largest reduction occurred in Q2 2023, reducing 196,436 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's ImmunityBio (IBRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly ImmunityBio (IBRX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +573,021 | New Buy | 573,021 | $7.67 |
| Q3 2025 | -16,407 | Sold Out | 0 | $0.00 |
| Q2 2025 | -7,846 | Reduce 32.35% | 16,407 | $2.64 |
| Q1 2025 | +24,253 | New Buy | 24,253 | $3.01 |
| Q3 2024 | -101,046 | Sold Out | 0 | $0.00 |
| Q2 2024 | +101,046 | New Buy | 101,046 | $6.32 |
| Q2 2023 | -196,436 | Sold Out | 0 | $0.00 |
| Q1 2023 | +196,436 | New Buy | 196,436 | $0.00 |
| Q3 2022 | -95,140 | Sold Out | 0 | $0.00 |
| Q2 2022 | +95,140 | New Buy | 95,140 | $3.72 |
Paul Tudor Jones's ImmunityBio Investment FAQs
Paul Tudor Jones first purchased ImmunityBio, Inc. (IBRX) in Q2 2022, acquiring 95,140 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held ImmunityBio, Inc. (IBRX) for 10 quarters since Q2 2022.
Paul Tudor Jones's largest addition to ImmunityBio, Inc. (IBRX) was in Q1 2026, adding 573,021 shares worth $4.4 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 573,021 shares of ImmunityBio, Inc. (IBRX), valued at approximately $4.4 M.
As of the Q1 2026 filing, ImmunityBio, Inc. (IBRX) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in ImmunityBio, Inc. (IBRX) was 573,021 shares, as reported at the end of Q1 2026.